Asset profile

vosoritide · BioMarin (BMRN)

Indication: achondroplasia
Also known as: VOXZOGO

Company

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic di…

Start live analysis of BMRN Run 8-agent AI analysis

On the calendar

Oct 2026

~ Oct 2026

BMRNBioMarin

BioMarin presents new VOXZOGO data at ASBMR 2026

Conference presentationCompany press releaseMonth only

Mar 2027

~ Mar 2027

BMRNBioMarin

vosoritide: Phase 2 trial NCT06668805 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Dec 2027

~ Dec 2027

BMRNBioMarin

vosoritide: Phase 2 trial NCT04554940 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Jun 2028

Jun 30, 2028

in 608 days

BMRNBioMarin

vosoritide: Phase 2 trial NCT07126262 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2028

Dec 31, 2028

in 792 days

BMRNBioMarin

vosoritide: Phase 1/Phase 2 trial NCT05845749 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Jun 2029

~ Jun 2029

BMRNBioMarin

vosoritide: Phase 2/Phase 3 trial NCT07441876 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Oct 2044

~ Oct 2044

BMRNBioMarin

vosoritide: Phase 3 trial NCT07073014 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.govMonth only

Timeline

Newest first.

Oct 9, 2026

09:05 PM

BMRNBioMarin

BioMarin presents new VOXZOGO data at ASBMR 2026

Conference presentationCompany press release

Oct 1, 2026

03:24 PM

BMRNBioMarin

vosoritide · NCT05849389 registry update

Trial registry changeClinicalTrials.gov Open record

Sep 23, 2026

03:21 PM

BMRNBioMarin

vosoritide · NCT06668805 registry update

Trial registry changeClinicalTrials.gov Open record1 update

Aug 6, 2026

08:06 PM

BMRNBioMarin

BioMarin submits sNDA for VOXZOGO in hypochondroplasia

Application submittedSEC 8-K Open record

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT04554940	Phase 2	Active, not recruiting	Dec 1, 2027	20	0 of 3 sites in the United States
NCT06668805	Phase 2	Active, not recruiting	Mar 1, 2027	30	21 of 38 sites in the United States
NCT07441876	Phase 2/3	Recruiting	Jun 1, 2029	160	9 of 28 sites in the United States
NCT07126262	Phase 2	Recruiting	Jun 30, 2028	60	10 of 26 sites in the United States
NCT07073014	Phase 3	Enrolling by invitation	Oct 1, 2044	140	10 of 30 sites in the United States
NCT05845749	Phase 1/2	Active, not recruiting	Dec 31, 2028	6	1 of 1 sites in the United States
NCT05849389	Phase 2	Unknown	Sep 1, 2026	20	1 of 1 sites in the United States
NCT04219007	Phase 2	Active, not recruiting	Aug 14, 2025	56	1 of 1 sites in the United States
NCT06382155	Phase 2	Recruiting	Jun 1, 2026	100	35 of 47 sites in the United States
NCT06455059	Phase 3	Active, not recruiting	Aug 1, 2026	80	4 of 23 sites in the United States

More from BioMarin

Other drugs and candidates from the same company tracked in this sector.

ALE1hypophosphatasia cipaglucosidase alfa-atgalate-onset Pompe disease HM15421Fabry disease